Featured Jobs
|
MAP Retirement
|
|
PPS Pension Services
|
|
Defined Contribution Account Manager Nova 401(k) Associates
|
|
Frank Pension Consultants, Ltd.
|
|
DWC - The 401(k) Experts
|
|
Relationship Manager - Defined Contributions Daybright Financial
|
|
DWC - The 401(k) Experts
|
|
Retirement Plan Onboarding Specialist Compass
|
Free Newsletters
“BenefitsLink continues to be the most valuable resource we have at the firm.”
-- An attorney subscriber
|
|
|
U.S. Senator Chides Pharmaceutical Company for Bumping $40 Drug with $2,000 Version
Contra Costa Times via Physicians for a National Health Program [PNHP] 
Nov. 30, 2007 Excerpt: Although it's not stopping the off-label use of [the company's $40 drug, Avastin], Genentech did announce in October a move that some fear will make it harder for physicians to prescribe the medication.... Some have asked Genentech to conduct a study comparing the effectiveness of [the company's $2,000 drug, Lucentis] and Avastin in treating [age-related macular degeneration], but the company has no plans to do so. MORE >> |
| Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the linked news item's title). |
| An important word about authorship: BenefitsLink® created this link to the news item, but we are not the news item's author (unless expressly shown above). |